Latham Advises on Scribe Therapeutics’ US$155.51 Million IPO

Scribe Therapeutics Inc. (Scribe Therapeutics) (Nasdaq: SCTX), a clinical‑stage biotechnology company engineering purpose‑built in vivo CRISPR technologies designed to extend healthy lifespan through disease prevention and durable therapeutic intervention, has announced the closing of its upsized initial public offering of 9,867,000 shares of its common stock, which includes the exercise in full by the underwriters of their option to purchase 1,287,000 additional shares, at the initial public offering price of US$15 per share. All of the shares were offered by Scribe Therapeutics. Scribe Therapeutics’ common stock began trading on the Nasdaq Global Market on July 24, 2026, under the ticker symbol SCTX.

Latham & Watkins LLP advised the underwriters in the offering with a Capital Markets team led by Orange County partners Shayne Kennedy and Ross McAloon, with associates Greg Van Buiten, Kennedy Holmes, and Austin Urbach. Advice was also provided on intellectual property matters by San Diego counsel Robert Yeh, with associate Patrick Chew; on data privacy and cybersecurity matters by Bay Area partner Heather Deixler and London counsel Oliver Mobasser; on healthcare matters by Bay Area partner Betty Pang; on FDA matters by Washington, D.C. counsel Chad Jennings; on executive compensation and employee benefits matters by Los Angeles/Orange County partner Michelle Carpenter and Orange County counsel Sara Schlau, with associate Genie Yae; and on tax matters by Los Angeles partner Eric Cho, with associate Joe Marcus.